Navigation Links
Verenium Corporation To Announce Fourth Quarter And Year End 2012 Financial Results
Date:3/18/2013

SAN DIEGO, March 18, 2013 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that it will release fourth quarter and year end 2012 financial results on Wednesday, March 27, 2013 after market close.  In conjunction with the release, the Company will host a conference call with live webcast on Wednesday, March 27, 2013 at 5:00 p.m. ET.

(Logo: http://photos.prnewswire.com/prnh/20120924/MM79973LOGO)

The call may be accessed by dialing (877) 755-7422 (domestic) or (678) 894-3067 (international) five minutes prior to start time and providing the passcode 22467056.  A link to the live webcast may be accessed by visiting the "Investors" section of the Company's website at http://ir.verenium.com/.  A replay of the event will be available on the Company's website approximately two hours after the call and will be archived for 30 days.

About Verenium
Verenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at www.verenium.com.

Forward Looking Statements
Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's estimated revenues, operating loss and capital expenditures for the year ended December 31, 2012, unrestricted cash balance as of December 31, 2012, near-term opportunities and long-term growth prospects, the impact of Verenium's restatement of certain of its historical financial statements on its consolidated balance sheets and consolidated statement of operations for the relevant periods and its cash position, and Verenium's San Diego facility and the related lease.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's audited financial results, capital expenditures and cash position for the year ended and as of December 31, 2012 being different from Verenium's estimated financial results, capital expenditures and cash position, the actual impact of Verenium's restatement of certain of its historical financial statements on its consolidated balance sheets and consolidated statement of operations for the relevant periods and its cash position being different from the estimated impact, Verenium's strategic focus, technologies, products and product candidates and product pipeline (including Verenium's ability to identify, develop and commercialize new products and product candidates, either independently or with collaborators or partners, and market demand for those products and product candidates), dependence on patents and proprietary rights,  protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements,  its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies, the timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture or partnership agreements and licenses on a timely basis or at all, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2011 and any updates contained in its subsequently filed quarterly reports on Form 10-Q .  These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.

Contact:

Sarah Carmody
Sr. Corporate Communications Manager
858-431-8581
sarah.carmody@verenium.com


'/>"/>
SOURCE Verenium Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Celladon Corporation Receives Notice of Allowance from United States Patent and Trademark Office
2. Sanford-Burnham and Intrexon Corporation establish collaboration to accelerate stem cell research
3. Statistics & Data Corporation Selects MedNet Solutions As Strategic Technology Partner
4. Eliza Corporation and BlueCross BlueShield of South Carolina Drive Awareness and Healthier Behavior to Increase Colorectal Cancer Screenings by 45 Percent
5. ShanghaiBio Corporation Partners with Ingenuity Systems to Address Challenges in Analysis and Interpretation of Genomics Data
6. Medbox, Inc. Announces Top-Tier Rating by Dun & Bradstreet Credibility Corporation
7. Scripps Research and Takeda Pharmaceuticals announce expanded research collaboration
8. Spiral Genetics Closes $3 Million in Funding Led by DFJ and Announces Partnership with Omicia
9. Wake Forest Innovations Announces New Commercialization Developments
10. MARC Travel Awards announced for Immunohistochemistry and Microscopy (IHCM) Short Course 2013
11. FASEB MARC Travel Awards announced for the 2013 American College of Sports Medicine Northwest Chapter Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... BETHESDA, Md. , June 22, 2016  The American ... by Trade Show Executive Magazine as one of ... Summit on May 25-27 at the Bellagio in ... based on the highest percentage of growth in each of ... number of exhibiting companies and number of attendees. The 2015 ...
(Date:6/21/2016)... June 21, 2016 NuData Security announced today ... role of principal product architect and that ... of customer development. Both will report directly to ... The moves reflect NuData,s strategic growth in its ... high customer demand and customer focus values. ...
(Date:6/15/2016)... , June 15, 2016 ... market report titled "Gesture Recognition Market by Application Market - Global ... 2016 - 2024". According to the report, the  global ... billion in 2015 and is estimated to grow ... 48.56 billion by 2024.  Increasing application ...
Breaking Biology News(10 mins):
(Date:12/7/2016)... ... 07, 2016 , ... JULABO USA is inviting visitors to ... website has been designed to provide the best user-friendly experience coupled with intuitive ... product information, read educational industry content as well as share information across all ...
(Date:12/7/2016)... ... 07, 2016 , ... Kara Dwyer Dodge grew up hearing stories of the sea monster her ... Mass., found a sea turtle entangled in the lines of one of his lobster pots. ... sensation because no one could remember ever seeing one so large so close to shore. ...
(Date:12/6/2016)... 2016 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; ... quarter and fiscal year ended September 30, 2016. ... , , ... and diagnostics company that develops and commercializes proprietary technologies and products ... Achieved revenues of $1.4 million more than tripling prior years ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... 2016 asking the Federal Drug Administration (FDA) to consider OA as a serious ... is concerned about the growing population of OA patients, many of whom may ...
Breaking Biology Technology: